The TSX Venture Exchange has accepted for filing the documentation relating to a subscription agreement dated Feb. 14, 2018, in connection with the acquisition of 2,283,495 shares of Habi Pharma Pty. Ltd.

As consideration for the acquisition, the company paid an aggregate consideration of approximately $2,657,950 (Australian) by the issuance of a total five million common shares of the company.

For further information, please refer to the company's press releases dated Jan. 22, 2018, and Feb. 15, 2018.